1. The effect of treatments for osteoporosis on mortality

   • A. Grey
   • M. J. Bolland

   Review 18 October 2012 Pages: 1 - 6

   

2. Life-course evidence of birth weight effects on bone mass: systematic review and meta-analysis

   • J. Martínez-Mesa
   • M. C. Restrepo-Méndez
   • A. M. B. Menezes

   Review 29 August 2012 Pages: 7 - 18

   

3. Erratum to: Life-course evidence of birth weight effects on bone mass: systematic review and meta-analysis

   • J. Martínez-Mesa
   • M. C. Restrepo-Méndez
   • A. M. B. Menezes

   Erratum 28 September 2012 Pages: 19 - 21

   

4. European guidance for the diagnosis and management of osteoporosis in postmenopausal women

   • J. A. Kanis
   • E. V. McCloskey
   • on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF)

   Position Paper Open access 19 October 2012 Pages: 23 - 57

   

5. Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

   • G. Ioannidis
   • J. Flahive
   • for the GLOW Investigators

   Original Article 12 April 2012 Pages: 59 - 67

   

6. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women

   • S. Tanaka
   • T. Kuroda
   • M. Shiraki

   Original Article 15 November 2012 Pages: 69 - 76

   

7. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study

   • S. Boutroy
   • D. Hans
   • R. Chapurlat

   Original Article 16 October 2012 Pages: 77 - 85

   

8. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men

   • S. Verschueren
   • E. Gielen
   • S. Boonen

   Original Article 10 July 2012 Pages: 87 - 98

   

9. A decreasing trend in fall-related hip fracture incidence in Victoria, Australia

   • E. Cassell
   • A. Clapperton

   Original Article 21 February 2012 Pages: 99 - 109

10. Depressive symptoms and rates of bone loss at the hip in older men

    • S. J. Diem
    • S. L. Harrison
    • for the Osteoporotic Fractures in Men (MrOS) Research Group

    Original Article 30 March 2012 Pages: 111 - 119

    

11. Relationship between use of antidepressants and risk of fractures: a meta-analysis

    • V. Rabenda
    • D. Nicolet
    • J.-Y. Reginster

    Original Article 26 May 2012 Pages: 121 - 137

    

12. Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products

    • F. J. B. Lötters
    • I. Lenoir-Wijnkoop
    • M. J. Poley

    Original Article Open access 16 June 2012 Pages: 139 - 150

    

13. Cost-effectiveness of nutritional intervention in elderly subjects after hip fracture. A randomized controlled trial

    • C. E. Wyers
    • P. L. M. Reijven
    • P. C. Dagnelie

    Original Article Open access 26 May 2012 Pages: 151 - 162

    

14. Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight

    • J. T. Schousboe
    • M. Gourlay
    • For the Osteoporotic Fractures in Men (MrOS) and Study of Osteoporotic Fractures (SOF) Research Groups

    Original Article 17 February 2012 Pages: 163 - 177

    

15. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study

    • H. P. Bhattoa
    • E. Nagy
    • P. Antal-Szalmas

    Original Article 16 March 2012 Pages: 179 - 186

16. Vitamin D status is associated with physical performance: the results of three independent cohorts

    • E. Sohl
    • R. T. de Jongh
    • N. M. van Schoor

    Original Article 08 September 2012 Pages: 187 - 196

    

17. Vitamin D₂ from light-exposed edible mushrooms is safe, bioavailable and effectively supports bone growth in rats

    • M. S. Calvo
    • U. S. Babu
    • S. Nagaraja

    Original Article 23 February 2012 Pages: 197 - 207

    

18. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis

    • N. Freemantle
    • C. Cooper
    • C. Roux

    Original Article 26 July 2012 Pages: 209 - 217

    

19. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

    • M. Shiraki
    • T. Sugimoto
    • T. Nakamura

    Original Article Open access 24 October 2012 Pages: 219 - 226

    

20. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

    • M. R. McClung
    • E. M. Lewiecki
    • P. D. Miller

    Original Article Open access 10 July 2012 Pages: 227 - 235

    

21. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges

    • D. H. Solomon
    • E. Mercer
    • N. Treister

    Original Article 16 June 2012 Pages: 237 - 244

    

22. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study

    • L. Bondo
    • P. Eiken
    • B. Abrahamsen

    Original Article 26 May 2012 Pages: 245 - 252

    

23. A meta-analysis characterizing the dose–response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women

    • J. Yates

    Original Article 26 October 2012 Pages: 253 - 262

    

24. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice

    • T. Thomas
    • S. Horlait
    • J. L. Lange

    Original Article 27 June 2012 Pages: 263 - 269

    

25. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study

    • J.-H. Kang
    • J. J. Keller
    • H.-C. Lin

    Original Article 14 November 2012 Pages: 271 - 277

    

26. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies

    • K. Sun
    • J. M. Liu
    • G. Ning

    Original Article 06 October 2012 Pages: 279 - 286

    

27. QCT bone mineral density responses to 1 year of oral bisphosphonate after total knee replacement for knee osteoarthritis

    • J. K. Lee
    • C. H. Lee
    • C. H. Choi

    Original Article 23 February 2012 Pages: 287 - 292

28. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

    • M. R. McClung
    • J. R. Zanchetta
    • P. Delmas

    Original Article Open access 30 June 2012 Pages: 293 - 299

    

29. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

    • M. R. McClung
    • A. Balske
    • R. R. Recker

    Original Article Open access 19 October 2012 Pages: 301 - 310

    

30. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia—a randomized placebo-controlled trial

    • R. D. Chapurlat
    • M. Laroche
    • M.-C. de Vernejoul

    Original Article 09 March 2012 Pages: 311 - 320

    

31. Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study

    • B. Abrahamsen
    • K. H. Rubin
    • R. Eastell

    Original Article 16 October 2012 Pages: 321 - 328

    

32. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial

    • L. Yang
    • A. V. Sycheva
    • R. Eastell

    Original Article 06 November 2012 Pages: 329 - 338

    

33. Effects of 3 years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients

    • S. Gamsjaeger
    • B. Hofstetter
    • E. P. Paschalis

    Original Article 15 November 2012 Pages: 339 - 347

    

34. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate

    • S. Bourke
    • M. J. Bolland
    • I. R Reid

    Original Article 15 August 2012 Pages: 349 - 354

    

35. Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis

    • A. Svedbom
    • L. Alvares
    • O. Ström

    Original Article 14 August 2012 Pages: 355 - 367

    

36. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database

    • B. Abrahamsen

    Short Communication 10 May 2012 Pages: 369 - 372

    

37. Ten-year hip fracture incidence rate trends in a large California population, 1997–2006

    • A. L. Adams
    • J. Shi
    • S. J. Jacobsen

    Short Communication 21 February 2012 Pages: 373 - 376

    

38. Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients

    • S. Pilz
    • A. Meinitzer
    • A. Fahrleitner-Pammer

    Short Communication 17 March 2012 Pages: 377 - 381

39. The cyclooxygenase-2 selective inhibitor NS-398 does not influence trabecular or cortical bone gain resulting from repeated mechanical loading in female mice

    • T. Sugiyama
    • L. B. Meakin
    • J. S. Price

    Short Communication Open access 14 February 2012 Pages: 383 - 388

    

40. Comment on Kanis et al.: Pitfalls in the external validation of FRAX

    • M. J. Bolland
    • A. Grey
    • I. R. Reid

    Letter 15 May 2012 Pages: 389 - 390

41. Pitfalls in the external validation of FRAX: response to Bolland et al.

    • J. A. Kanis
    • A. Oden
    • E. McCloskey

    Letter 15 May 2012 Pages: 391 - 392